Furthermore, we found that doxorubicin induced Gal-9 expression in a time- and dose-dependent manner, as shown in Fig. 2B. Gal-9 expressed on the cell surface of cancer cells exerts immunosuppressive effects by binding to TIM-3 on T cells 12. Here, HAVCR2 is linked to cancer.